Sociedad Quimica Y Minera De Chile
SQM
64.61
-1.56
-2.36%
Sociedad Quimica Y Minera De Chile
US · SQM
#974 by market cap
Listed 1970
64.61
-1.56
-2.36%
Live - 5344 symbols - heartbeat 473s ago
· 2026-10-08 07:38
Pre-market
64.60
-0.02%
After-hours
64.61
0.00%
Overnight
64.62
+0.02%
- Market cap
- 18.46B
- P/E (TTM)i
- 13.30
- P/Bi
- 2.92
- EPSi
- 2.06
- Div yieldi
- 1.59%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on SQM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 3.00, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +1.05% YoY
Margins
- Gross margin
- 29.56%
- Operating margin
- 23.37%
- Net margin
- 12.85%
Key ratios & quality
- Enterprise valuei
- 20.41B
- Altman Z-Scorei
- 3.00
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.27B | 1.94B | 1.82B | 2.86B | 10.71B | 7.47B | 4.53B | 4.58B |
| Gross profit | 780.17M | 560.05M | 482.87M | 1.09B | 5.74B | 3.08B | 1.33B | 1.35B |
| Selling & admin expenses | 131.49M | 121.40M | 174.27M | 154.39M | 146.70M | 154.73M | 228.79M | 213.55M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 633.55M | 422.93M | 292.55M | 921.73M | 5.57B | 2.88B | 1.06B | 1.07B |
| Pretax profit | 621.04M | 390.62M | 238.54M | 841.22M | 5.49B | 2.81B | 974.41M | 960.73M |
| Tax | 178.98M | 110.02M | 70.18M | 249.02M | 1.57B | 1.88B | 282.57M | 320.08M |
| Net profit | 442.06M | 280.60M | 168.36M | 592.21M | 3.91B | 930.27M | 691.84M | 640.64M |
| Basic EPS | 2 | 1 | 1 | 2 | 14 | 3 | 2 | 2 |
| Diluted EPS | 1.66 | 1.05 | 0.63 | 2.05 | 13.68 | 3.23 | 2.40 | 2.06 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.04B | 1.04B | 1.17B | 1.32B | 1.76B | 2.47B |
| Gross profit | 304.70M | 253.00M | 345.81M | 448.53M | 778.60M | 1.26B |
| Selling & admin expenses | 43.40M | 47.60M | 44.92M | 61.03M | 48.90M | 52.40M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 261.30M | 205.40M | 285.81M | 368.82M | 729.70M | 1.21B |
| Pretax profit | 211.70M | 147.00M | 265.65M | 336.40M | 686.80M | 1.17B |
| Tax | 73.40M | 57.60M | 85.60M | 103.53M | 283.90M | 454.40M |
| Net profit | 138.30M | 89.40M | 180.05M | 232.88M | 402.90M | 719.20M |
| Basic EPS | 0 | 0 | 1 | 1 | 1 | 2 |
| Diluted EPS | 0.48 | 0.31 | 0.62 | 0.64 | 1.28 | 2.31 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 2.40B | 2.68B | 2.57B | 4.59B | 6.99B | 5.87B | 5.58B | 5.78B |
| Cash & ST investments | 847.86M | 1.07B | 854.56M | 2.42B | 3.61B | 2.36B | 2.44B | 2.72B |
| Inventory | 913.67M | 983.34M | 1.09B | 1.18B | 1.78B | 1.77B | 1.70B | 1.80B |
| Total assets | 4.27B | 4.68B | 4.82B | 7.18B | 10.82B | 11.71B | 11.50B | 14.50B |
| Total current liabilities | 555.66M | 776.81M | 475.88M | 991.71M | 3.05B | 2.35B | 2.22B | 1.77B |
| Short-term debt | 15.45M | 288.47M | 42.39M | 48.38M | 486.58M | 1.23B | 1.18B | 458.67M |
| Long-term debt | 1.32B | 1.47B | 1.89B | 2.51B | 2.37B | 3.21B | 3.58B | 4.22B |
| Total liabilities | 2,130,292,000.00 | 2,549,679,000.00 | 2,655,885,000.00 | 3,964,230,000.00 | 5,887,100,000.00 | 6,138,665,000.00 | 6,297,502,000.00 | 6,451,081,000.00 |
| Total equity | 2.14B | 2.13B | 2.16B | 3.22B | 4.93B | 5.57B | 5.20B | 8.05B |
| Retained earnings | 1.62B | 1.62B | 1.64B | 1.65B | 3.35B | 3.84B | 3.62B | 4.03B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.60B | 5.49B | 5.52B | 5.78B | 6.98B | 7.66B |
| Cash & ST investments | 2.35B | 2.23B | 2.39B | 2.72B | 3.87B | 4.35B |
| Inventory | 1.79B | 1.85B | 1.84B | 1.80B | 1.88B | 1.90B |
| Total assets | 11.49B | 11.52B | 11.73B | 14.50B | 15.78B | 16.65B |
| Total current liabilities | 1.94B | 1.88B | 1.96B | 1.77B | 2.53B | 2.94B |
| Short-term debt | 910.82M | 910.15M | 901.52M | 458.67M | 324.40M | 425.70M |
| Long-term debt | 3.76B | 3.77B | 3.75B | 4.22B | 4.79B | 4.79B |
| Total liabilities | 6,194,514,000.00 | 6,130,351,000.00 | 6,194,339,000.00 | 6,451,081,000.00 | 7,563,200,000.00 | 7,971,700,000.00 |
| Total equity | 5.29B | 5.39B | 5.53B | 8.05B | 8.22B | 8.68B |
| Retained earnings | 3.72B | 3.78B | 3.90B | 4.03B | -- | -- |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- | -- | -- |
| Free cash flow | 205.77M | 103.16M | -140.59M | 357.80M | 3.17B | -1.30B | 302.89M | 437.69M |
| Dividends paid | -550.35M | -329.79M | -222.00M | -571.70M | -2.24B | -1.47B | -67.22M | -4.27M |
| Stock buybacks / issuance | -- | -- | 0 | 1.10B | -- | -- | -- | -- |
| Ending cash balance | 556.07M | 588.53M | 509.10M | 1.52B | 2.66B | 1.04B | 1.38B | 1.75B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -- | -- | -- | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | 38.12M | -104.90M | 187.86M | 316.61M | -- | -- |
| Dividends paid | -4.08M | -611.00K | -612.00K | 1.03M | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 1.66B | 1.57B | 1.49B | 1.75B | -- | -- |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 20.59 | 13.33 | 7.82 | 22.07 | 96.71 | 38.60 | -7.56 | 10.84 |
| ROA %i | 10.27 | 6.21 | 3.46 | 9.87 | 43.74 | 17.87 | -3.49 | 4.52 |
| ROIC %i | 13.60 | 8.51 | 5.40 | 12.97 | 57.93 | 22.63 | -3.42 | 6.38 |
| 5-year avg ROE %i | 14.39 | 15.00 | 14.63 | 16.62 | 32.10 | 31.53 | 31.43 | 32.03 |
| EBIT margin %i | 29.87 | 23.78 | 17.75 | 32.26 | 52.07 | 39.27 | 25.67 | 24.92 |
| FCF / sales %i | 9.08 | 5.31 | -- | 12.50 | 29.62 | -- | 6.69 | 9.56 |
| Current ratioi | 4.32 | 3.45 | 5.40 | 4.62 | 2.29 | 2.50 | 2.51 | 3.27 |
| Quick ratioi | 2.59 | 2.12 | 3.02 | 3.34 | 1.67 | 1.68 | 1.71 | 2.20 |
| Debt / assetsi | 31.25 | 38.23 | 40.55 | 36.35 | 26.90 | 38.37 | 41.92 | 32.60 |
| LT debt / equityi | 63.22 | 72.02 | 90.04 | 80.51 | 49.50 | 58.98 | 70.53 | 75.02 |
| Interest coveragei | 12.16 | 6.46 | 3.84 | 11.25 | 61.92 | 23.39 | 6.18 | 6.35 |
| Revenue CAGR (3Y) %i | 9.45 | 0.07 | -5.56 | 8.10 | 76.63 | 60.17 | 16.53 | -24.68 |
| Net income CAGR (3Y) %i | 25.91 | -0.02 | -27.27 | 10.00 | 141.28 | 77.70 | 5.38 | -46.80 |
| FCF CAGR (3Y) %i | -13.32 | -40.92 | -- | 20.25 | 213.39 | -- | -5.40 | -48.34 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.17 | 9.28 | 9.92 | 10.84 | 14.68 | 23.78 |
| ROA %i | 5.46 | 4.28 | 4.56 | 4.52 | 5.98 | 9.85 |
| ROIC %i | 6.99 | 5.49 | 5.78 | 6.38 | 8.31 | 13.32 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 24.01 | 22.03 | 23.11 | 24.92 | 30.48 | 39.44 |
| FCF / sales %i | 8.12 | -- | 1.52 | 9.56 | -- | -- |
| Current ratioi | 2.88 | 2.92 | 2.82 | 3.27 | 2.76 | 2.61 |
| Quick ratioi | 1.89 | 1.86 | 1.82 | 2.20 | 1.86 | 1.84 |
| Debt / assetsi | 41.13 | 41.10 | 40.15 | 32.60 | 32.40 | 31.33 |
| LT debt / equityi | 72.59 | 71.47 | 69.32 | 75.02 | 81.81 | 75.91 |
| Interest coveragei | 5.67 | 5.01 | 5.50 | 6.35 | 9.01 | 13.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Lithium and its derivatives is the largest reported line at 50.00% of revenue, across 6 reported segments.
- Iodine and its derivatives follows at 22.79%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Lithium and its derivatives50.00%
Iodine and its derivatives22.79%
Specialty plant nutrients21.47%
Potassium3.40%
Industrial Chemicals1.65%
Other products and services0.70%
Region
Asia and others62.98%
North America15.06%
Europe14.31%
Latin America and the Caribbean4.11%
Chile3.53%
Quote time 2026-10-08 07:38:28 · For reference only, not investment advice and not tailored to your situation.